Genovac to Present Latest Innovations in Antibody Discovery Against Difficult Targets at Antibody Engineering & Therapeutics Conference in San Diego

Fargo, North Dakota, Dec. 13, 2021 — Genovac, a contract research and manufacturing organization specializing in antibody discovery against challenging targets, will be presenting at this year’s Antibody Engineering & Therapeutics (AE&T) conference in San Diego, Dec 13-16.

Amelie Kutschera, MSc., single B cell scientist at Genovac, will deliver a presentation entitled Leading Strategies for Antibody Discovery Against Difficult Targets –Genetic Immunization and Berkeley Lights Beacon®” onWednesday, December 15, from 12:00 p.m. – 12:30 p.m. PT. Kutschera will discuss the limited success traditional hybridoma and phage display methods have had in delivering therapeutic antibodies against difficult targets and how Genovac has overcome this challenge by leveraging their proprietary genetic immunization technology and Berkeley Lights’ Beacon Optofluidic system.

“For many years, the combination of DNA immunization and hybridoma screening technologies was the leading approach for the generation of high-affinity antibodies against challenging therapeutic targets,” said Brian Walters, Genovac, CEO. “Today, powerful new screening technologies are redefining discovery possibilities for more challenging targets such as GPCRs and ion channels. Using the Berkeley Lights Beacon Optofluidic system along with Genovac’s innovations in DNA immunization, we’re able to significantly increase project success, diversity and yield from a variety of animal species, enabling our clients’ programs with valuable drug candidates.”

Genovac scientists will be attending the live AE&T conference in San Diego and will be available to discuss new discovery, development and productions capability questions at Booth #204.

About Genovac

Genovac is a contract research and manufacturing organization offering the world’s most advanced antibody discovery solutions. Its immunization technologies, combined with advanced hybridoma and the Berkeley Lights Beacon platform, enable success against the most challenging targets. Since its founding in 1999, Genovac has completed more than 3,500 projects, providing antibodies to clients in North America, Europe, Australia and Asia that have been developed into clinical and commercial drugs. In addition to its headquarters and labs in Fargo, North Dakota, Genovac operates a second scientific and production facility in Freiburg, Germany.

Media Contact